Compliance and fixed-dose combination therapy

Current Hypertension Reports

Volumn 9, Issue 3, 2007, Pages 184-189

  Bangalore, Sripal ^b   Shahane, Anupama ^b   Parkar, Sanobar ^b   Messerli, Franz H ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FELODIPINE; FELODIPINE PLUS RAMIPRIL; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL; PERINDOPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOOT EDEMA; GLUCOSE INTOLERANCE; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; HYPERTENSION; KINESIOTHERAPY; MEDICATION ERROR; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; POLYPHARMACY; POTASSIUM DEPLETION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; RISK FACTORS; TREATMENT REFUSAL;

EID: 34250212952     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0033-3     Document Type: Review

References (45)

1. Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
2. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000, 356:1955-1964.
3. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
4. Cheung BM, Ong KL, Man YB, et al.: Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006, 8:93-98.
5. Oparil S, Calhoun DA: Managing the patient with hard-to-control hypertension. Am Fam Physician 1998, 57:1007-1014, 1019-20.
6. Stephenson J: Noncompliance may cause half of antihypertensive drug "failures." JAMA 1999, 282:313-314.
7. National Council on Patient Information and Education: The other drug problem: statistics on medicine use and compliance. Bethesda, MD: National Council on Patient Information and Education; 1997.
8. Ziegelstein RC: Adherence to medication regimens and recommended lifestyle changes in patients with cardiovascular disease. Adv Stud Med 2003, 3:150-156.
9. Michalsen A, Konig G, Thimme W: Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998, 80:437-441.
10. Dezii CM: Medication noncompliance: what is the problem? Manag Care 2000, 9:7-12.
11. World Health Organization: Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO; 2003.
12. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS: Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521-530.
13. Haynes RB, Taylor DW, Sachett DL: Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979.
14. Su WJ, Perng RP: Fixed-dose combination chemotherapy (Rifater/ Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002, 6:1029-1032.
15. Wetzels GE, Nelemans P, Schouten JS, Prins MH: Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004, 22:1849-1855.
16. Schroeder K, Fahey T, Hollinghurst S, Peters TJ: Nurse-led adherence support in hypertension: a randomized controlled trial. Fam Pract 2005, 22:144-151.
17. Taylor AA, Shoheiber O: Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCI versus comparable component-based therapy. Congest Heart Fail 2003, 9:324-332.
18. Wogen J, Kreilick CA, Livornese RC, et al.: Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003, 9:424-429.
19. Melikian C, White Tj, Vanderplas A, et al.: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002, 24:460-467.
20. Awad AG: Antipsychotic Medications in Schizophrenia: How Satisfied Are Our Patients? United Kingdom: Shire Hall International; 1999.
21. Al-Yahya AA, Al-Mehza AM, Al-Ghareeb H: Comparison of compliance versus non-compliance to anti-hypertensive agents in primary health care - an area-based study. Kuwait Medical Journal 2006, 38:28-32.
22. Skelding PC, Majumdar SR, Kleinman K, et al.: Clinical and nonclinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization. J Clin Hypertens (Greenwich) 2006, 8:414-419.
23. Li WW, Stewart AL, Stotts N, Froelicher ES: Cultural factors associated with antihypertensive medication adherence in Chinese immigrants. J Cardiovasc Nurs 2006, 21:354-362.
24. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
25. Neaten JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:S6-64.
26. Dusing R: Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006, 22:1545-1553.
27. Wolff JL, Starfield B, Anderson G: Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002, 162:2269-2276.
28. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
29. Waeber B: Achieving blood pressure targets in the management of hypertension. Blood Press Suppl 2001, 2:6-12.
30. Wacber B, Brunner HR: The multifactorial nature of hypertension: the greatest challenge for its treatment? J Hypertens Suppl 2001, 19:S9-S16.
31. McInnes GT: How important is optimal blood pressure control? Clin Ther 2004, 26(Suppl A):A3-A11.
32. Blank R, LaSalle J, Reeves R, et al.: Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/ atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005, 7:264-273.
33. Dezii CM: A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000, 9:2-6.
34. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH: Fixed-dose combination improves medication compliance: a meta-analysis. Am J Med 2007, In press.
35. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
36. Reddy KS: The preventive polypill - much promise, insufficient evidence. N Engl J Med 2007, 356:212.
37. Sica DA: Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002, 62:443-462.
38. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
39. Kjeldsen SE, Os I, Hoieggen A, et al.: Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005, 5:17-22.
40. Messerli FH, Grossman E: Pedal edema - not all dihydropyridine calcium antagonists are created equal. Am J Hypertens 2002, 15:1019-1020.
41. Weir MR: Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003, 5:330-335.
42. Fogari R, Zoppi A, Derosa G, et al.: Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007, 21:220-224.
43. Messerli FH, Weir MR, Neutel JM: Combination therapy of amlodipine/ benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002, 15:550-556.
44. van der Heijden AG, Huysmans FT, van Hamersvelt HW: Foot volume increase on nifedipine is not prevented by pre-treatment with diuretics. J Hypertens 2004, 22:425-430.
45. Scholze J, Bida M, Hansen A, et al.: Initiation of hypertension treatment with a fixed-dose combination or its monocomponents - does it really matter? Int J Clin Pract 2006, 60:265-274.